"Following the Cass review, NHS England commissioned an in-depth review of all available clinical evidence for using estrogen or testosterone either alone or with other medications to treat gender incongruence and dysphoria. This review has established that the available evidence does not support the continued use of masculinizing or feminizing hormones to treat gender incongruence or dysphoria for young people under 18."
"That study recommended 'extreme caution' initiating hormone treatments, including estrogen and testosterone, and a 'clear clinical rationale for providing hormones at this stage rather than waiting until an individual reaches 18.'"
The NHS announced a pause on new referrals for gender-affirming hormone treatments for adolescents aged 16-17 experiencing gender dysphoria. This decision follows the 2024 Cass Report and a subsequent NHS-commissioned review of clinical evidence. The new report concludes that available evidence does not support continued use of masculinizing or feminizing hormones for treating gender incongruence or dysphoria in people under 18. The Cass Review recommended extreme caution when initiating hormone treatments and questioned the clinical rationale for providing hormones before age 18. This NHS action follows an earlier indefinite ban on puberty-suppressing drugs for transgender minors enacted by the UK government in December 2024, with officials citing unacceptable safety risks.
Read at LGBTQ Nation
Unable to calculate read time
Collection
[
|
...
]